Our round-up of biotech financings is led this week by Braveheart Bio, a San Francisco biotech that has launched with $185 million, a lead drug for hypertrophic cardiomyopathy (HCM), and Biogen CEO ...
The federal government is waging a war on higher education. The reason is obvious: universities are bastions of free thinking, deep thinking, critical thinking — and thinking, in all its forms, is ...
Bristol Myers Squibb currently has the only drug approved specifically for treating obstructive hypertrophic cardiomyopathy, a debilitating disorder that can progress to heart failure. But safety ...
With $185 million in series A funding and an army of experienced leaders in its ranks, Braveheart Bio is setting off to joust with big names in an emerging heart disease drug arena. Backed by ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It’s one of the largest ...
Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.
A weapon used by Mel Gibson while he played the Scots hero of William Wallace in Braveheart has sold for over £8,000 at auction. Fans of the award winning film were given the opportunity to snap up ...
W e write as scholars of academic freedom to respond to the proposed “Compact for Academic Excellence in Higher Education.” We are politically diverse and do not share common views about the wisdom of ...
Neon CEO and founder Tom Quinn has called for solidarity in the film industry to defend the right to freedom of expression, suggesting that some executives are failing to “hold the line”. Quinn ...
Conservative influencer Benny Johnson posted footage on Saturday about a large crowd of people in line to get a Charlie Kirk "FREEDOM" t-shirt in the parking lot of Penn State's Beaver Stadium. Penn ...
Braveheart Bio has waded into the fight for a heart disease market, paying (PDF) $65 million upfront for a rival to Bristol Myers Squibb’s Camzyos and Cytokinetics’ aficamten. Jiangsu Hengrui ...
WASHINGTON—The House Freedom Caucus is no longer the most feared group of GOP lawmakers on Capitol Hill. And headed into the next fight with fellow Republicans over keeping the government funded this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback